Leonidas G Koniaris

Dr. Leonidas G Koniaris


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2006 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SKStephen J. Kovach
Stephen J. Kovach
AFAnne C. Fischer
Anne C. Fischer
PKPhilip J. Katzman
Philip J. Katzman
RSRabih M. Salloum
Rabih M. Salloum
SEStephen E. Ettinghausen
Stephen E. Ettinghausen
LKLeonidas G Koniaris
Leonidas G Koniaris

14 April 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JRJoseph E. Rupert
Joseph E. Rupert
ANAshok Narasimhan
Ashok Narasimhan
DJDaenique H.A. Jengelley
Daenique H.A. Jengelley
YJYanlin Jiang
Yanlin Jiang
JLJianguo Liu
Jianguo Liu
TZTeresa A. Zimmers
Teresa A. Zimmers
Most patients with pancreatic adenocarcinoma (PDAC) suffer cachexia; some do not. To model heterogeneity, we used patient-derived orthotopic xenografts. These phenocopied donor weight loss. Furthermore, muscle wasting correlated with mortality and murine IL-6, and human IL-6 associated with the greatest murine cachexia. In cell culture and mice, PDAC cells elicited adipocyte IL-6 expression and IL-6 plus IL-6 receptor (IL6R) in myocytes and blood. PDAC induced adipocyte lipolysis and muscle steatosis, dysmetabolism, and wasting. Depletion of IL-6 from malignant cells halved adipose wasting and abolished myosteatosis, dysmetabolism, and atrophy. In culture, adipocyte lipolysis required soluble (s)IL6R, while IL-6, sIL6R, or palmitate induced myotube atrophy. PDAC cells activated adipocytes to induce myotube wasting and activated myotubes to induce adipocyte lipolysis. Thus, PDAC cachexia results from tissue crosstalk via a feed-forward, IL-6 trans-signaling loop. Malignant cells signal via IL-6 to muscle and fat, muscle to fat via sIL6R, and fat to muscle via lipids and IL-6, all targetable mechanisms for treatment of cachexia.

3 November 2008 in Cancer
Verified
Journal Article
Open access
PDF file
MMManuel A. Molina
Manuel A. Molina
MCMichael C. Cheung
Michael C. Cheung
EPEduardo A. Perez
Eduardo A. Perez
MBMargaret M. Byrne
Margaret M. Byrne
DFDido Franceschi
Dido Franceschi
LKLeonidas G Koniaris
Leonidas G Koniaris
BACKGROUND.: Differences in cancer survival based on race, ethnicity, and socioeconomic status (SES) are a major issue. To identify points of intervention and improve survival, the authors sought to determine the impact of race, ethnicity, and socioeconomic status for patients with cancers of the head and neck (HN).METHODS.: HN cancer patients diagnosed between 1998 and 2002 were examined using a linked Florida Cancer Data System and Florida Agency for Health Care Administration data set.RESULTS.: A total of 20,915 patients with HN cancers were identified, predominantly in the oral cavity and larynx. Overall, 72% of patients were male, 89.7% were white, 8.4% were African American (AA), and 10.6% were Hispanic. The median survival time (MST) was 37 months. MST varied significantly by race (white, 40 months vs AA, 21 months; P < .001), sex (men, 36 months vs women, 41 months; P = .001), and area poverty level (lowest, 27 months vs highest, 34 months; P < .0001). Only 32% of AA patients underwent surgery in comparison with 45% of white patients (P < .001). On multivariate analysis, independent predictors of poorer outcomes were race, poverty, age, sex, tumor site, stage, grade, treatment modality, and a history of smoking and alcohol consumption.CONCLUSIONS.: Carcinomas of the HN have an overall high mortality with a disproportionate impact on AA patients and the poor. Dramatic disparities by race and SES are not explained completely by demographics, comorbid conditions, or undertreatment. Earlier diagnosis and greater access to surgery and adjuvant therapies in these patients would likely yield significant improvement in outcomes. Cancer 2008. © 2008 American Cancer Society.

22 February 2006 in Hepatology
Verified
Journal Article
Open access
PDF file
XJXiaoling Jin
Xiaoling Jin
TZTeresa A. Zimmers
Teresa A. Zimmers
EPEduardo A. Perez
Eduardo A. Perez
RPRobert H. Pierce
Robert H. Pierce
ZZZongxiu Zhang
Zongxiu Zhang
LKLeonidas G Koniaris
Leonidas G Koniaris
Interleukin-6 (IL-6) is an important mediator of liver regeneration and repair that is also elevated in chronic liver diseases, including fatty liver of obesity and cirrhosis. IL-6 has been reported both to delay and accelerate liver regeneration. We examined the effects on liver injury and regeneration of a continuous administration of exogenous IL-6 to mice by injection of an IL-6–expressing CHO-cell line in athymic nude mice and by osmotic mini-pump delivery of recombinant murine IL-6. Short-term IL-6 administration (1-2 days) accelerated early recovery of liver mass, whereas more long-term administration (5-7 days) markedly impaired liver regeneration. Similarly, short-term IL-6 treatment increased hepatic resistance to the lethal effects of the Fas agonist Jo-2, but on more prolonged IL-6 exposure the Jo-2 resistance vanished. IL-6 administration initially induced expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL, correlating with protection against Fas-mediated cell death. More prolonged IL-6 administration, however, resulted in marked induction of the pro-apoptotic protein Bax. This result coincided with increased activation of the type II or intrinsic, mitochondrial path to cell death, manifested by increased caspase-9 activation and increased cytochrome c release after Jo-2 exposure. These data demonstrate that IL-6 can function acutely to improve hepatic regeneration and repair, but that more chronic exposure not only abolishes the protective effects of IL-6, but actually sensitizes the liver to injury and death. In conclusion, elevated IL-6 in certain chronic liver diseases contributes to an increased likelihood of liver failure after injury. (Hepatology 2006;43:474–484.)

1 January 2009 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MCMichael C. Cheung
Michael C. Cheung
KHKara Hamilton
Kara Hamilton
RSRecinda Sherman
Recinda Sherman
MBMargaret M. Byrne
Margaret M. Byrne
DNDao M. Nguyen
Dao M. Nguyen
LKLeonidas G Koniaris
Leonidas G Koniaris

1 April 2008 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
MCMichael C. Cheung
Michael C. Cheung
EPEduardo A. Perez
Eduardo A. Perez
MMManuel A. Molina
Manuel A. Molina
XJXiaoling Jin
Xiaoling Jin
JGJuan C. Gutierrez
Juan C. Gutierrez
LKLeonidas G Koniaris
Leonidas G Koniaris